Evidence map›Paper›PMID 30766139›Full record

ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2016

FDA Black Box, VA Red Ink? A Successful Service-Connected Disability Claim for Chronic Neuropsychiatric Adverse Effects From Mefloquine.

Remington L Nevin, Elspeth Cameron Ritchie

Abstract read
In one paragraph

Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Misclassification and Bias in Military Studies of Mefloquine.The American journal of tropical medicine and hygiene · 2017
    Article
  3. Screening for Symptomatic Mefloquine Exposure Among Veterans With Chronic Psychiatric Symptoms.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Remington L Nevinis a postdoctoral fellow in the Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland. is chief of community-based outpatient clinics, mental health at the Washington DC VAMC and a clinical professor of psychiatry at the Uniformed Services University of the Health Sciences in Bethesda, Maryland; at Georgetown University School of Medicine, George Washington University School of Medicine, and at Howard University School of Medicine; all in Washington, DC. Dr. Ritchie is also a member of the Federal Practitioner Editorial Advisory Association.
Elspeth Cameron Ritchieis a postdoctoral fellow in the Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland. is chief of community-based outpatient clinics, mental health at the Washington DC VAMC and a clinical professor of psychiatry at the Uniformed Services University of the Health Sciences in Bethesda, Maryland; at Georgetown University School of Medicine, George Washington University School of Medicine, and at Howard University School of Medicine; all in Washington, DC. Dr. Ritchie is also a member of the Federal Practitioner Editorial Advisory Association.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More veterans are likely to present to the VA with service-connected claims for adverse effects related to exposure to a prophylactic antimalarial drug commonly used by the military for more than 2 decades.

Identifiers

PMID30766139
PMCPMC6373714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.